ABSTRACT -Capecitabine is an oral anticancer prodrug which is converted to 5-fluorouracil (5-FU) via 3 enzymatic steps, these being 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and finally 5-FU by carboxylesterase (CES), cytidine deaminase (CDA), and thymidine phosphorylase (TP), respectively. Because rats, mice and monkeys are used for preclinical safety studies, we investigated the in vitro conversion from capecitabine to 5-FU by hepatic and intestinal mucosal microsomes and cytosols, to compare their metabolic activity to that of humans. Capecitabine was hydrolyzed to 5'-DFCR in hepatic and intestinal mucosal microsomes in these animal species. In humans and monkeys, CL int (V max /K m ) for the hydrolysis of capecitabine in intestine (expressed as μl/min/g tissue) was much lower than that in hepatic microsomes but, in rats and mice, CL int was higher in intestine than in liver. In humans and monkeys, similar K m values and inhibition patterns by tetrahydrouridine (THU) a CDA inhibitor, were observed in CDA activity of hepatic and intestinal cytosols. However, rats showed very low CDA activity and mice showed non-Michaelis-Menten kinetics and a different inhibition pattern by THU. K m values for TP activity were almost similar in rats, mice, monkeys and humans. In conclusion, it was confirmed that monkeys are a suitable animal model for the safety assessment of capecitabine in terms of metabolic enzymes and it was suggested that higher toxic incidences in mouse small intestine were related to high hydrolytic activity of capecitabine in the small intestine.
INTRODUCTION
Capecitabine (Xeloda®) is a widely-used oral fluoropyrimidine carbamate for the treatment of colorectal and breast cancers (Walko and Lindley, 2005) . Capecitabine alone or a regimen of capecitabine plus oxaliplatin (XELOX) is used for advanced or metastatic colorectal cancers (Van Cutsem et al., 2001; Cassidy et al., 2008) and the drug is also used as an adjuvant therapy for colorectal cancers. Recently the combination of bevacizumab, a recombinant humanized monoclonal antibody to the vascular endothelial growth factor VEGF, with capecitabine or XELOX is now considered to be a standard treatment for colorectal cancers (Fuchs et al., 2007; ReinacherSchick et al., 2008; Moehler et al., 2009) .
Capecitabine was designed rationally as a prodrug that would pass intact through the intestinal mucosa and would be sequentially converted to 5-fluorouracil (5-FU) by a 3-step enzymatic activation in the liver and tumor tissues (Fig. 1 , Miwa et al., 1998; Shimma et al., 2000) . First, the carbamate moiety of capecitabine is hydrolyzed to 5'-DFCR by carboxylesterase (CES) primarily in the liver (Miwa et al., 1998; Tabata et al., 2004a) . Secondly, 5'-DFCR is converted to 5'-DFUR by cytidine deaminase (CDA), the activity of which is highly observed in liver and tumor tissues (Camiener and Smith, 1965; Miwa et al., 1998) . Then, 5'-DFUR is converted to 5-FU by thymidine phosphorylase (TP), which is located in many organs and is highly expressed in tumor tissue (Yoshimura et al., 1990; Miwa et al., 1998) . Higher activity of TP in tumor tissue than normal tissue caused higher concentration of 5-FU in tumor tissue than normal tissue in human clinical samples. It was reported that the mean tissue/plasma 5-FU concentration ratios exceeded 20 for colorectal tumor and the mean concentration of 5-FU in colorectal tumor was 3.2-times higher than in adjacent healthy tissue after capecitabine treatment (Schüller et al., 2000) . Therefore, preferential activation of capecitabine to 5-FU in colorectal tumor was demonstrated.
One of the dose-limiting toxicities (DLT) of 5'-DFUR (doxifluridine, Furtulon®) was diarrhea in breast cancer patients with oral administration (Taguchi et al., 1985) . It is considered that this is caused by 5'-DFUR being converted to 5-FU by intestinal TP during the absorption process. In the case of capecitabine, as it likely passes through the intestinal mucosa as an intact molecule, production of 5-FU in intestinal mucosa is thought to be lower than with 5'-DFUR and therefore may induce lower toxicity in the intestine. We have reported that the toxicity of capecitabine in monkeys was reduced compared with that of 5'-DFUR based on mmol/kg dose and AUC of 5'-DFUR (Shindoh et al., 2006) .
In the present study, we examined how the act of converting capecitabine to 5-FU relates to toxicity, especially intestinal toxicity, and its species difference. We used microsomes as an enzyme source for CES and used a cytosolic enzyme source for CDA and TP activities. Our choice was guided by earlier reports in which the clearance of capecitabine to 5'-DFCR in liver microsomes was approximately 5-fold higher than that in cytosol, and hydrolysis was inhibited by CES inhibitors (Tabata et al., 2004a) ; capecitabine was partially hydrolyzed by human liver cytosol and was characterized as CES1A1 (Tabata et al., 2004b) ; and the formation of 5'-DFUR and 5-FU from capecitabine was observed only by cytosol and was inhibited by CDA and TP inhibitors, respectively (Tabata et al., 2004a) . We measured CL int of CES, CDA and TP activity in hepatic and intestinal mucosal microsomes and cytosol in mice, rats, monkeys and humans. We compared these metabolic enzyme activities and toxic effects in experimental animals used for the safety studies of capecitabine and humans. microsomes and cytosols were prepared as described below. Pooled human hepatic microsomes (pool of 50, mixed gender, Lot 0710593, 0710091, and 0810509) and cytosols (pool of 50, Lot 0410131, 0710594, and 0710099) were purchased from Xenotech LLC (Lenexa, KA, USA). Pooled human intestinal microsomes (pool of 4M6F 045359820007, pool of 10F 045306060011, pool of 8M2F 045411880006) and cytosols (pool of 10F 045274220005, pool of 2M3F 045187640002, pool of 2M1F HJC-0056R) were purchased from KAC (Shiga, Japan) as products of T-Cubed Inc. (Edison, NJ, USA). These intestinal microsomes and the cytosol were prepared by EDTA-eluting method from human jejunum (Zhang et al., 1999) . Microsomes and cytosol were stored at -80°C and were used within 3 freeze-thaw cycles.
Preparation of hepatic and intestinal microsomes and cytosols from rats, mice and monkeys Nine-week-old male Sprague-Dawley rats (n = 8) and 9-week-old male BDF1 mice (n = 16) were anesthetized by isoflurane inhalation and blood was withdrawn from an aorta or by heart puncture, respectively. The liver and small intestine were removed after withdrawal of blood. Rat and mouse livers were weighed and perfused with icecold saline through the large veins with a syringe. Livers were minced with scissors before homogenization. Hepatic microsomes and cytosol were prepared individually from 3 rats. Livers from 2 mice were pooled as one lot and 3 different lots of microsomes and cytosol were prepared. The small intestine was divided in half into upper and lower parts and the inside of the lumen was washed with ice-cold saline. Intestines were cut longitudinally and mucosa was exposed. The mucosa of the upper and lower small intestines and large intestine was scraped off using a slide glass and was pooled in an ice-cold container. After weighing the mucosa, intestinal mucosa from 2 to 3 rats or 5 to 6 mice was pooled and 3 different lots of microsomes and cytosols were prepared. The mouse microsomes from the lower small intestine and large intestine and cytosol from the large intestine were pooled in one lot each because the yield amount was too small to prepare 3 lots.
Five-year-old male cynomolgus monkeys (n = 3) were anesthetized with an intravenous injection of pentobarbital (approximately 32 mg/kg) and blood was withdrawn from a cannulated jugular aorta. A piece of liver (approximately 5 g) was cut out, weighed, and perfused with ice-cold saline through the veins. The liver was minced with scissors in ice-cold saline and washed by decantation three times. After the small intestine had been removed, it was divided in half into upper and lower parts and the inside of the lumen was washed with ice-cold saline. Intestines were cut longitudinally and mucosa was exposed. The mucosa of the upper and lower small intestines and large intestine was scraped off using a slide glass and was individually pooled in an ice-cold container.
Minced liver or intestinal mucosa was homogenized in 3 volumes of 50 mM Tris-HCl buffer (pH 7.4) containing 0.15 M KCl, 1 mM EDTA, 100 μM dithiothreitol (DTT) and 3 unit/ml heparin using a Potter-Elvehjem homogenizer with a Teflon pestle under ice-cold conditions. The homogenate was centrifuged at 9,000 × g for 20 min at 4°C and the supernatant was centrifuged at 105,000 × g for 60 min at 4°C. The pellets were resuspended in 250 mM sucrose as hepatic or intestinal microsomes and the supernatant was used as hepatic or intestinal cytosols. Microsomes and cytosols were divided into aliquots and stored at -80°C. Cytosol for the measurement of TP activity was dialyzed against 20 mM phosphate buffer (pH 7.4) containing 100 μM DTT overnight at 4°C according to the method of Miwa (Miwa et al., 1998) . Protein concentration of microsomes and cytosols was measured by BCA protein assay kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) using bovine serum albumin as the standard. The intestinal microsomes prepared from the upper small intestine were used in the following kinetic and inhibition studies.
HPLC conditions
5'-DFCR, 5'-DFUR and 5-FU concentrations were measured by gradient high performance liquid chromatography (HPLC) with UV detection as described by Tabata (Tabata et al., 2004a) , with minor modifications. HPLC analysis was performed using LC-10ADvp pumps (Shimadzu, Kyoto, Japan), SPD-10Avp detector (Shimadzu), SIL-10ADvp autosampler (Shimadzu), SCL10Avp controller (Shimadzu), CTO-10Avp column oven (Shimadzu), and data integrator Empower2 (Waters, Milford, MA, USA). The analytical column was Develosil C30-UG-5, 150 × 4.6 mm (Nomura Chemical Co. Ltd., Aichi, Japan). The flow rate was 1.0 ml/min and the column temperature was 30°C. The mobile phase was solvent A (10 mM sodium phosphate buffer, pH 4.8) and solvent B (80% methanol). The mobile phase flow was 3%B from 0 min to 9 min, increased to 45%B with linear gradient from 9 min to 20 min, again increased to 100%B with linear gradient from 20 to 23 min, was maintained at 100%B from 23 min to 28 min, then decreased to 3%B from 28 min to 30 min. The total analytical time was 35 min. In the case of analyzing 5-FU only, the mobile phase flow was 3%B from 0 min to 9 min, increased to 100%B with linear gradient from 9 min to 12 min, was maintained at 100%B from 12 min to 20 min, then decreased to 3%B from 20 min to 25 min. UV detection was set at 265 nm. The retention times for 5-FU, 5-chlorouracil (internal standard), 5'-DFCR and 5'-DFUR were 4. 8, 8.8, 16 .5, and 17.8 min, respectively. The linearity of standard curves for 5'-DFCR, 5'-DFUR and 5-FU concentrations was observed from 1 to 1,000 μM.
Enzyme assays
Hydrolysis of capecitabine to 5'-DFCR (CES activity): An incubation mixture consisting of 50 mM phosphate buffer (pH 7.4), 1 mM EDTA, 100 μM THU and 0.5 mg protein/ml of microsomes (225 μl) was warmed for 3 min at 37°C and 25 μl of capecitabine solution was added to initiate the reaction. After incubation at 37°C for 30 min, 500 μl of acetonitrile was added to the reaction mixture and it was centrifuged at 1,940 × g for 5 min. The supernatant was evaporated under N 2 stream. The residue was dissolved in 100 μl of water and the solution was centrifuged at 9,100 × g for 5 min. Twenty μl of the supernatant was injected into the HPLC system. The enzyme activity was linear up to 1 or 2 mg protein/ml of microsomes and up to 60 min of incubation time in rat, mouse, monkey and human hepatic microsomes.
Conversion from 5'-DFCR to 5'-DFUR (CDA activity): CDA activity was measured according to the method of Miwa (Miwa et al., 1998) . Incubation mixture consisted of 50 mM Tris-acetate buffer (pH 7.4) and 1 mg protein/ml of cytosol (180 μl). The incubation mixture was warmed for 3 min at 37°C and 20 μl of 5'-DFCR solution was added to initiate the reaction. After incubation at 37°C for 30 min, 1.0 ml of ethyl acetate and 200 μl of 0.05 M HCl containing 10 μg/ml 5-chlorouracil solution (internal standard) was added to the mixture. It was mixed for 10 sec. with a vortex mixer and centrifuged at 1,940 × g for 5 min. The upper layer was collected and the extraction was repeated twice. The upper layer was combined and evaporated under N 2 stream. The residue was dissolved in 100 μl of water and 20 μl was injected into the HPLC system. The enzyme activity was linear up to 2 mg protein/ml of cytosolic protein and up to 60 min of incubation time in monkey hepatic and intestinal cytosols.
Conversion from 5'-DFUR to 5-FU (TP activity): TP activity was measured according to the method of Miwa (Miwa et al., 1998) . Incubation and extraction procedures were the same as the measurement of CDA activity described above and 5'-DFUR was added to the incubation mixture as a substrate for 5'-DFCR. The enzyme activity was linear up to 0.5 mg protein/ml of cytosol protein and up to 45 min of incubation time in monkey hepatic and intestinal cytosols.
The CES activity was calculated from the concentration of 5'-DFCR generated and expressed as nmol/min/mg microsomal (MS) protein. The V max value was expressed as nmol/min/mg MS protein and nmol/min/g tissue which was calculated as follows: (nmol/min/g tissue) = (nmol/ min/mg MS protein) × (mg MS protein/g tissue). For the liver MS protein content, 48.8 and 44.8 mg MS protein/g tissue for human and rat, respectively, were used from literature (Iwatsubo et al., 1997) . The human value, 48.8, was used for that of monkey and the rat value, 44.8, was used for that of mouse. For the upper small intestinal MS protein content, 2.1-2.6, 3.3-4.2 and 0.50-0.60 mg MS protein/g tissue for rats, mice and monkeys, respectively, was determined by the following calculations. The total MS protein (mg) yielded from pooled upper small intestinal mucosa in the present study was divided by 1/3 of the gut volume values of rats (11.3 ml), mice (1.5 ml) and monkeys (230 ml) from literature (Davies and Morris 1993) . For human jejunum, MS protein content was calculated to be 0.32 mg MS protein/g tissue as follows: total MS protein amount of jejunum (133 mg, segments 2-4) prepared by EDTA-eluting method from literature (Zhang et al., 1999) was divided by the wet weight of jejunum, a value of 411 g from literature (Paine et al., 1997) .
The CDA activity was calculated from the formation of 5'-DFUR plus 5-FU as a reduction of 5'-DFCR and expressed as nmol/min/mg cytosol protein. The TP activity was calculated from the formation of 5-FU and expressed as nmol/min/mg cytosol protein.
Estimation of kinetic parameters
Hydrolysis of capecitabine to 5'-DFCR was measured at the concentrations from 0.25 to 16 mM of capecitabine, CDA activity was measured from 0.125 to 8 mM of 5'-DFCR and TP activity was measured from 0.25 to 16 mM of 5'-DFUR. Capecitabine was dissolved in 10% dimethylsulfoxide (DMSO) solution and 5'-DFCR and 5'-DFUR were dissolved in water at 10-fold concentration. Microsomal concentration was 0.5 mg protein/ml for hydrolysis of capecitabine and cytosol concentration was 0.25 to 1 mg protein/ml for CDA and 0.25 mg protein/ ml for TP activity. The conversion activities were measured as described above and K m and V max values were determined by fitting the Michaelis-Menten plot using WinNonlin software ver. 5.2.1 (Pharsight, Co., Mounten View, CA, USA).
Inhibition studies
The inhibitory effect of BNPP (CES inhibitor, Brandt et al., 1980) on the hydrolysis of capecitabine was measured at its final concentrations of 0, 1, 10, 100 and 1,000 μM. The 10-fold concentration of BNPP was dissolved in water and 25 μl of BNPP solution was added to 200 μl of incubation mixture containing 0.5 mg protein/ml microsomes. Rat, mouse, monkey and human hepatic and intestinal microsomes were used for the study. Incubation was initiated by adding 25 μl of capecitabine solution at the final concentration of 0.5 mM. Formation of 5'-DFCR was measured after incubation for 30 min at 37°C. Remaining activity was calculated against mean activity at 0 μM of BNPP. The inhibitory effect of THU (CDA inhibitor, Wentworth and Wolfenden, 1975) on CDA activity was measured at its final concentrations of 0, 0.1, 1 and 10 μM. The 100-fold concentration of THU was dissolved in water and 2 μl of THU solution was added to 178 μl of incubation mixture containing 1 mg protein/ml of cytosol (0.25 mg protein/ml for monkey intestinal cytosol). Human and monkey hepatic or intestinal cytosols and mouse intestinal cytosol were used for the study. The incubation was initiated by adding 20 μl of 5'-DFCR solution at the final concentration of 0.5 or 1 mM 5'-DFCR. Formation of 5'-DFUR plus 5-FU was measured after incubation for 30 min at 37°C. Remaining activity was calculated against mean activity at 0 μM of THU.
RESULTS

Comparison of conversion activities in upper or lower small intestines and large intestine in rats, mice and monkeys
Hydrolysis of capecitabine to 5'-DFCR (CES), conversion from 5'-DFCR to 5'-DFUR (CDA), and conversion of 5'-DFUR to 5-FU (TP) activity levels in upper or lower small intestine and large intestine are shown in Fig. 2 . In mice, hydrolysis of capecitabine in upper small intestine was much higher than that in lower small intestine and was further decreased in large intestine. In monkeys, hydrolysis of capecitabine in upper and lower small intestine was similar and was much lower than that in mice. Only a trace level of CDA activity was observed in small and large intestinal cytosols in rats. CDA activity in mice was lower than that in monkeys. High CDA activity was observed in monkeys and the activity in their upper and lower small intestines and large intestine was similar. TP activity in upper and lower small intestine was similar in rats, mice, and monkeys. TP activity in large intestine was relatively lower than that in small intestine.
Hydrolysis of capecitabine to 5'-DFCR in hepatic or intestinal microsomes in rats, mice, monkeys and humans
The kinetic parameters for hydrolysis of capecitabine to 5'-DFCR in rats, mice, monkeys and humans are shown in Table 1 . Capecitabine was hydrolyzed to 5'-DFCR by rat, mouse, monkey and human hepatic and intestinal mucosal microsomes. V max values are also calculated as nmol/min/g tissue in order to express the metabolic ability in tissue level instead of that in microsomal protein. In humans and monkeys, V max /K m values expressed as μl/min/g tissue are approximately 69-to 209-fold higher in liver than those in intestine (liver: 106.7 and 106.6 μl/min/g tissue, intestine: 0.51 and 1.54 μl/min/g tissue, respectively). On the other hand, intestinal V max /K m values in mice and rats (51.2 and 16.3 μl/min/g tissue) are much higher than those in humans and monkeys (0.51 and 1.54 μl/min/g tissue, respectively).
CDA activity in hepatic or intestinal cytosols in rats, mice, monkeys, and humans
The kinetic profile for CDA activity in rats, mice, monkeys and humans is shown in Fig. 3 and kinetic parameters in monkeys and humans are presented in Table 2 . Rat hepatic cytosol did not convert 5'-DFCR to 5'-DFUR and rat intestinal cytosol showed very low activity at high concentrations (more than 4 mM). Mouse hepatic cytosol also showed low CDA activity. Mouse intestinal cytosol showed low CDA activity at a low substrate concentration (below 1 mM), but at the higher concentrations (more than 2 mM), the CDA activity increased linearly up to 8 mM without saturation. Mouse hepatic and intestinal cytosol showed non-Michaelis-Menten kinetics. For these reasons, we could not calculate K m and V max values for mouse and rat cytosols. Monkey and human hepatic and intestinal cytosols showed Michaelis-Menten kinetics and K m values of hepatic and intestinal cytosol were very similar at 1.0 and 0.94 mM in monkeys and 1.6 and 1.4 mM in humans, respectively. V max value of monkey intestinal cytosol was much higher than that of human (22.1 vs. 1.7 nmol/min/ mg) and V max /K m of monkey intestinal cytosol was also higher than that of human (23.3 vs. 1.2 μl/min/mg), while those in liver were similar between humans and monkeys.
TP activity in hepatic or intestinal cytosols in rats, mice, monkeys, and humans
The kinetic parameters for TP activity in rats, mice, monkeys and humans are shown in Table 3 . Hepatic and intestinal cytosols of all the animal species converted 5'-DFUR to 5-FU. K m values for rat, mouse, monkey and human hepatic and intestinal cytosols were almost simi- small intestines and large intestine in rats, mice and monkeys. Hydrolysis of capecitabine was measured at 0.5 mM capecitabine and 0.5 mg protein/ml microsomes. CDA or TP activities were measured at 0.5 mM 5'-DFCR or 5'-DFUR and 0.25 mg protein/ml cytosol for monkeys and 1 mg protein/ml cytosol for rats and mice. Data are expressed as mean ± S.D.
(n = 3/group). *: pooled sample (n = 1). lar, ranging from 1.0 mM to 2.7 mM; however, V max values varied from 5.7 to 36.1 nmol/min/mg. V max /K m values of monkey and human hepatic cytosols were higher than those of rat and mouse hepatic cytosols (19.0 and 12.3 μl/min/mg vs. 3.9 and 2.6 μl/min/mg, respectively).
Inhibitory effects of BNPP on hydrolysis of capecitabine to 5'-DFCR
The inhibitory effect of BNPP on hydrolysis of capecitabine to 5'-DFCR by rat, mouse, monkey and human hepatic and intestinal microsomes is shown in Fig. 4 . The hydrolysis of capecitabine by hepatic and intestinal microsomes prepared from each of the animal species was inhibited by BNPP but the inhibition pattern varied between species. IC 50 values for mouse hepatic and mouse and rat intestinal microsomes were less than 1 μM while those for human hepatic and human and monkey intestinal microsomes were approximately 1 μM, and for monkey and rat hepatic microsomes were approximately 10 μM.
Inhibitory effect of THU on CDA activity
The inhibitory effect of THU on CDA activity by human and monkey hepatic and human, monkey and mouse intestinal cytosols is presented in Fig. 5 . The inhibition patterns of human and monkey cytosols by THU were very similar. The IC 50 value was approximately 0.1 μM in human and monkey hepatic and intestinal cytosols and 80% to 90% inhibition was observed at 1 μM. On the other hand, CDA activity was not inhibited by THU up to 1 μM in mouse intestinal cytosol and was inhibited by about 70% at 10 μM.
Comparison of intestinal toxicity and systemic exposure in mice and monkeys
The histopathological changes of small and large intestines treated with capecitabine in mice at 1.1 and 2.2 mmol/kg/day and monkeys at 0.5 and 1.0 mmol/kg/ day for 4 weeks and the toxicokinetics are summarized in Table 4 (data are from Shindoh et al., 2006) . The systemic exposure of 5'-DFUR AUC was almost the same at 2.2 mmol/kg in mice and 0.5 mmol/kg in monkeys. As for the histopathological examinations, degeneration of nuclei of crypt cells was observed in duodenum, jejunum and ileum at 1.1 (+: 2/6) and 2.2 mmol/kg (+: 3/6, ++: 2/6 or 1/6) in mice but was not observed in small intestine in monkeys at 0.5 mmol/kg. Severe degeneration of nuclei of crypt cells was observed in small and large intestines in monkeys at 1.0 mmol/kg.
DISCUSSION
Capecitabine was hydrolyzed to 5'-DFCR by rat, mouse, monkey and human hepatic and intestinal mucosal microsomes and the hydrolysis was inhibited by BNPP. Miwa et al. (1998) reported that hydrolytic activity of capecitabine in liver was much higher than that in intestine (approximately 80 and 5 nmol/mg/hr, respectively) in humans using 700 × g supernatant of whole organ homogenates at 5 mM of capecitabine as substrate. Shimma et al. (2000) also reported that hydrolytic activity for liver and intestine was 190 nmol/mg/hr and < 10 nmol/mg/hr, respectively, in similar experimental conditions. In the present study, we purchased human intestinal microsomes prepared from jejunum enterocytes using an EDTA-eluting method (Zhang et al., 1999) . The activity was 5.1 nmol/min/mg MS protein (= 306 nmol/mg MS/hr) for liver and 3.56 nmol/min/mg MS protein (= 214 nmol/ mg MS/hr) for intestine at 4 mM of capecitabine as substrate. These differences are considered to be due to the difference in enzyme sources: crude 700 × g supernatant of whole liver or intestinal tissue and microsomes from liver or intestinal enterocytes. The protein concentration of 700 × g supernatant of liver homogenate is unknown, but that of 9,000 × g supernatant (S9) of liver homogenate is about 5 times higher than that of microsomes (inhouse data). The specific activity for liver microsomes is considered to be 5 times higher than that of S9 and therefore the activity of microsomes can be roughly converted as the activity of S9 divided by the ratio of protein con- centration. The present data from microsomes is converted 61.2 nmol/mg/hr (306 nmol/mg/hr divided by 5) as the activity of S9. Although the specific activity for 700 × g supernatant is considered to be lower than that of S9, activity converted as S9 is almost comparable with the previous data, 80 nmol/mg/hr. For intestinal homogenate, total protein amount of S9 prepared from whole human jejunum tissue was calculated from literature as follows: 35.1 mg protein/g tissue (Tsukamoto et al., 2001 ) × 411 g jejunum wet weight (Paine et al., 1997) = 14,426 .1 mg. Total protein content of jejunum enterocyte microsomes was reported to be 133 mg (Zhang et al., 1999) . The specific activity for enterocyte microsomes is considered to be 109 times (14,426 mg protein divided by 133 mg MS protein) higher than that of S9. Therefore, hydrolytic activity of enterocyte microsomes in the present study can be converted to that of S9 of whole jejunum homogenate to be 1.97 nmol/mg/hr (214 nmol/mg MS/hr divided by 109) which is considered to be a similar tendency to that of previous data on colo-rectal tissue (approximately 5 nmol/mg/hr, Miwa et al., 1998) .
However, since the microsomal contents in intestinal enterocytes are very low, the contribution of intestinal hydrolysis of capecitabine is considered to be very limited in vivo. The total microsomal protein contents in human liver are calculated as 82,472 mg: 48.8 mg/g liver (Iwatsubo et al., 1997 ) × 1,690 g liver weight (Davies and Morris, 1993) , and the protein content of jejunum enterocyte microsomes was 133 mg (Zhang et al., 1999) . The ratio of enterocyte microsomes to liver microsomes is calculated as only 0.16%. In addition, intrinsic clearance (CL int , V max /K m ) at organ level was calculated to be 180.3 ml/min/liver (106.7 μl/min/g tissue × 1,690 g liver weight) and 0.21 ml/min/jejunum (0.51 μl/ min/g tissue × 411 g jejunum weight) for liver and jejunum, respectively. The ratio of CL int of jejunum to that of liver is calculated as only 0.12%. The present K m and V max values in liver (5.7 mM and 604.8 nmol/min/g tissue) and intestine (7.2 mM and 3.66 nmol/min/g tissue) are comparable with previous data determined using S9 of liver (6.4 mM and 423 nmol/min/g tissue) and intestine (3.2 mM and 5.34 nmol/min/g tissue) (Tsukamoto et al., 2001) . These results suggested that hydrolysis of capecitabine is very low in intestine and most capecitabine is absorbed as intact drug and enters into the blood circulation. Then, capecitabine is converted to 5'-DFCR predominantly in the liver in humans.
In monkeys, CL int of hydrolysis of capecitabine was 106.6 and 1.54 μl/min/g tissue in liver and intestine, respectively. The ratio of hydrolysis in intestine to that of liver in monkeys is calculated to be 1.4% which is similar to that of humans at 0.48%. However, in rats and mice, the ratio of hydrolysis in intestine to that of liver is calculated as 20.6% and 17.0%, respectively, which is much higher than those of humans and monkeys. Shimma et al. (2000) have reported that capecitabine was more highly hydrolyzed by liver homogenate than intestinal homogenate in human but was more highly hydrolyzed by intestinal homogenate than liver homogenate in mice. In the present study, a similar tendency was confirmed (CL int : 6.7 and 13.7 μl/min/mg MS protein for liver and intestinal microsomes, respectively, in mice). Degeneration of nuclei of crypt cells was observed in duodenum, jejunum and ileum in mice at 1.1 and 2.2 mmol/kg but was not observed in monkeys at 0.5 mmol/kg. The systemic exposure of 5'-DFUR AUC in mice at 2.2 mmol/kg (25.0-46.3 μg·hr/ml) was almost similar to that in monkeys at 0.5 mmol/kg (26.1-35.8 μg·hr/ml). On the other hand, CL int (μl/min/g tissue) for hydrolysis of capecitabine to 5'-DFCR in upper small intestine in mice was 33-fold higher than that in monkeys. This suggests that sequential conversion of capecitabine to 5'-DFCR, 5'-DFUR and 5-FU is likely to be caused at local sites of small intestine during absorption in mice. Therefore, the high incidence of intestinal toxicity in small intestine is caused by high conversion of capecitabine in mice compared with that in monkeys at the same 5'-DFUR AUC. On the other hand, hydrolytic activity in upper small intestine was 8 times higher than that in lower small intestine in mice, but similar intestinal toxicity was observed from duodenum to ileum. Another possibility is that mice might be more sensitive than monkeys to intestinal toxicity. Further investigation might be needed to confirm the relation of intestinal toxicity and conversion of capecitabine in intestine.
In monkeys at 1.0 mmol/kg, more severe intestinal toxicity was observed in small and large intestines with higher exposure of 5'-DFUR AUC (approximately 50 to 60 μg·hr/ml). The toxicity in small and large intestines at high doses might be caused by circulating metabolite of capecitabine 5'-DFUR, which was converted to 5-FU by TP in the small and large intestines. 5'-DFUR AUC after a single oral administration at the clinical dose (~1,250 mg/m 2 of capecitabine) in cancer patients has been reported as 11.7 to 16.0 μg·hr/ml (Reigner et al., 2001) , therefore daily exposure is 23.4 to 32.0 μg·hr/ml, twice the daily administration. This exposure level was almost similar to that in monkeys at 0.5 mmol/kg, which induced very slight toxicity. However, 5'-DFUR AUC of 50 to 60 μg·hr/ml produced severe toxicity in monkeys at 1.0 mmol/kg. If plasma AUC of 5'-DFUR was increased to this level by genetic variation of metabolic enzymes of capecitabine, severe toxicity would occur in humans. In a recently reported case, severe digestive toxicity occurring in a low-dose capecitabine-treated patient was linked with an extensive-CDA syndrome (Mercier et al., 2009 ). Therefore, it might be useful to monitor extensive metabolizers of CDA to avoid severe toxicity of capecitabine in clinic.
CDA and TP activity in human hepatic and intestinal cytosol in the present study was consistent with previous data. CDA activity in hepatic and intestinal cytosol was 5.35 and 0.99 nmol/mg/min, respectively, at 2 mM substrate in the present study, and approximately 3.2 and 0.8 nmol/mg/min, respectively, at 2 mM substrate in the previous study (Miwa et al., 1998) . TP activity in hepatic and intestinal cytosol was 12.5 and 5.23 nmol/mg/min, respectively, at 8 mM substrate in the present study, and approximately 150 and 30 μg 5-FU/mg/hr (= 19.2 and 3.8 nmol/ mg/min), respectively, at 10 mM substrate in the previous study (Miwa et al., 1998) . Species difference in CDA activity was observed in rats, mice, monkeys and humans. K m values and inhibition patterns by THU in hepatic and intestinal cytosol were very similar between humans and monkeys. However, very low CDA activity was observed in hepatic and intestinal cytosol in rats. Non-Michaelis-Menten kinetics and a different inhibition pattern by THU were observed in mice. These results suggested that mouse CDA might be quite different from that of human and monkey, or a different enzyme might metabolize 5'-DFCR to 5'-DFUR in mice. However, as high CDA activity was reported in mouse kidney (Onodera et al., 2000) , it may be necessary to compare CDA activity and inhibition patterns using mouse kidney cytosol. K m values of CDA activity by human and monkey hepatic and intestinal cytosols were very similar but V max value in monkey intestine was much higher than that of human intestine. V max /K m for CDA activity in monkey intestinal cytosol (23.3 μl/min/mg) was approximately 20-fold higher than that of human (1.2 μl/min/mg). Although high CDA activity was observed in intestine, toxicity was not observed in small intestine in monkeys at 0.5 mmol/kg whereas mice showed toxicity in small intestine at a similar 5'-DFUR AUC. This suggests that since conversion of capecitabine to 5'-DFCR is lower in monkeys, high CDA activity may not influence further production of 5-FU in small intestine.
From the point of metabolic enzymes of capecitabine, cynomolgus monkeys are considered to be suitable animals for safety assessment by the following results: (1) hydrolytic activity of capecitabine in the liver and intestine is close to that of humans, (2) CDA and TP activities are highly expressed, (3) enzyme character of CDA is similar to that of humans. Mice have 3 metabolic enzymes of capecitabine but high CES activity was observed in small intestine and the character of CDA was different from that of humans. Rats and dogs (data not shown) have very low or no CDA activity. Therefore the ability to convert 5'-DFCR to 5'-DFUR was very low and sequential metabolism to 5-FU was very low or not observed in rats and dogs. In conclusion, it was confirmed that monkeys are a suitable animal model for the safety assessment of capecitabine in terms of metabolic enzymes, and it was suggested that higher toxic incidences in the small intestine in mice were related to high hydrolytic activity of capecitabine in the small intestine.
